KSI-101 in MESI: Multiple-dose results from APEX Phase 1b study in the U.S. and a clinical cohort of Asian patients from tertiary uveitis centers End of Study Weeks 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg KSI-101 intravitreal injection Key inclusion criteria • Macular edema secondary to inflammation (MESI) • Diagnosis of active or inactive non-infectious intraocular inflammation, acute or chronic • Active leakage as evidenced by fluorescein angiogram • OCT CST of ≥320 microns • BCVA score ≤75 and ≥25 (20/32 to 20/320 Snellen equivalent) Baseline Characteristics *Pharmacokinetics, tolerability and clinical activity of KSI-101 was evaluated in a clinical cohort of Asian patients at tertiary uveitis centers in Taiwan Study Design: Open-label Phase 1b in MESI APEX U.S. (N=41) Asia* KSI-101 2.5 mg (n=13) KSI-101 5 mg (n=14) KSI-101 10 mg (n=14) KSI-101 pooled (N=13) Age, years, mean (SD) 74.2 (11.6) 67.4 (8.1) 67.5 (18.8) 49.9 ( 22.6) Female, n (%) 8 (61.5) 7 (50.0) 8 (57.1) 11 (84.6) Race, Asian, n (%) 0 1 (7.1%) 0 13 (100) Race, White, n (%) 11 (84.6) 11 (78.6) 14 (100) 0 MESI disease duration, months , mean (SD) 12.2 (21.0) 1.7 (1.2) 15.8 (37.2) 2.3 ( 1.9) Inflammation anatomical location, n (%) Anterior 0 2 (14.3) 0 1 (7.7) Intermediate 1 (7.7) 0 2 (14.3) 2 (15.4) Posterior 10 (76.9) 6 (42.9) 10 (71.4) 6 (46.2) Panuveitis 2 (15.4) 6 (42.9) 2 (14.3) 5 (38.5) Patients with active inflammation, n (%) 3 (23.1) 11 (78.6) 5 (35.7) 12 (92.3) Unilateral MESI, n (%) 9 (69.2) 6 (42.9) 5 (35.7) 4 (30.8) BCVA, ETDRS Letters , mean (SD) 62.7 (7.4) 65.6 (7.9) 62.1 (8.4) 58.5 (14.1) Snellen equivalent ~20/50 ~20/50 ~20/63 ~20/63 OCT CST, μm , mean (SD) (Site reported) 461.7 (137.7) 487.0 (124.1) 528.6 (157.3) 429.8 (76.3) Lens Status, pseudophakic, n (%) 9 (69.2) 13 (92.9) 11 (78.6) 7 (53.8) 45